Targeting the gut microbiota for cancer therapy
Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of
cancer therapy, most notably immunotherapy and its immune-related adverse effects. The …
cancer therapy, most notably immunotherapy and its immune-related adverse effects. The …
Key determinants of success in fecal microbiota transplantation: From microbiome to clinic
Fecal microbiota transplantation (FMT) has achieved satisfactory results in preventing the
recurrence of Clostridioides difficile infection, but these positive outcomes have only been …
recurrence of Clostridioides difficile infection, but these positive outcomes have only been …
The person-to-person transmission landscape of the gut and oral microbiomes
The human microbiome is an integral component of the human body and a co-determinant
of several health conditions,. However, the extent to which interpersonal relations shape the …
of several health conditions,. However, the extent to which interpersonal relations shape the …
Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4
Metagenomic assembly enables new organism discovery from microbial communities, but it
can only capture few abundant organisms from most metagenomes. Here we present …
can only capture few abundant organisms from most metagenomes. Here we present …
Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation
S Federici, S Kredo-Russo, R Valdés-Mas… - Cell, 2022 - cell.com
Human gut commensals are increasingly suggested to impact non-communicable diseases,
such as inflammatory bowel diseases (IBD), yet their targeted suppression remains a …
such as inflammatory bowel diseases (IBD), yet their targeted suppression remains a …
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Previous studies have suggested that the gut microbiome influences the response to
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases
Fecal microbiota transplantation (FMT) is highly effective against recurrent Clostridioides
difficile infection and is considered a promising treatment for other microbiome-related …
difficile infection and is considered a promising treatment for other microbiome-related …
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
The composition of the gut microbiome has been associated with clinical responses to
immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific …
immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific …